1361990-92-2

Upstream product

• 2550-36-9 Cyclohexylmethyl bromide 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 
• 887475-71-0 6-bromo-8-methylsulfanyl-imidazo[1,2-a]pyrazine 
• 887475-94-7 8-(methylthio)imidazo[1,2-a]pyrazine-6-carbonitrile 
• 887475-95-8 3-bromo-8-(methylthio)imidazo[1,2-a]pyrazine-6-carbonitrile 
• 827614-68-6 N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1263425-52-0 tert-butyl 3-bromo-8-((tetrahydro-2H-pyran-4-yl)methylamino)imidazo[1,2-a]pyrazin-6-yl(cyclohexylmethyl)carbamate 
• 1263425-48-4 ethyl 3-bromo-8-(methylthio)imidazo[1,2-a]pyrazine-6-carboxylate 
• 1263425-49-5 3-bromo-8-(methylthio)imidazo[1,2-a]pyrazine-6-carboxylic acid 
• 1263425-50-8 tert-butyl 3-bromo-8-(methylthio)imidazo[1,2-a]pyrazin-6-ylcarbamate 
• 1263425-51-9 tert-butyl 3-bromo-8-(methylthio)imidazo[1,2-a]pyrazin-6-yl(cyclohexylmethyl)carbamate 

Downstream Products

• 1263422-96-3 4-(6-(cyclohexylmethylamino)-8-((tetrahydro-2H-pyran-4-yl)methylamino)imidazo[1,2-a]pyrazin-3-yl)-N-cyclopropylbenzamide 

Relevant academic research and scientific papers

FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION

Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR1—, ═N—, —CR7═), (—CR2═, ═N—, ═N—, —CR7═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NRA—, etc.; Z is a group represented by the formula —NR3R4 or a group represented by the formula —OR5; R1 to R3, R6, and R7 each is a hydrogen atom, etc.; R4 and R5 each is an (un)substituted alkyl, etc.; and R8 is an (un)substituted cycloalkyl, etc.